Tag: Inventiva
Inventiva: cash flow down in the 1st quarter – 05/17/2022 at 08:35
(CercleFinance.com) – Inventiva claims a cash position of 80.5 million euros as of March 31, 2022, compared to 95.4 million as of December 31, 2021, and specifies that it did…
Inventiva: loan agreement signed with the EIB
(CercleFinance.com) – Inventiva announces the signature of an ‘in fine’ credit agreement for a total amount of 50 million euros with the European Investment Bank (EIB), credit consisting of two…
Inventiva: Loan agreement signed with the EIB
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Inventiva: selection of an abstract on Lanifibranor
(CercleFinance.com) – Inventiva announces the selection of an abstract on its Lanifibranor, for a presentation in plenary session at the third International Conference on Fatty Liver to be held from…
Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver – 04/07/2022 at 22:00
Daix (France), Long Island City (New York, United States), April 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of small molecules…
Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver – 04/07/2022 at 22:00
Daix (France), Long Island City (New York, USA) April 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of orally administered small…
Inventiva announces the filing of its 2021 Universal Registration Document and its 2021 Annual Report (“Form 20-F”) – 03/11/2022 at 10:30 p.m.
Daix (France), Long Island City (New York, United States), March 11, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of small molecules…
Inventiva announces the filing of its 2021 Universal Registration Document and its 2021 Annual Report (“Form 20-F”) – 03/11/2022 at 10:44 p.m.
Daix (France), Long Island City (New York, USA) March 11, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of orally administered small…
Inventiva can continue its phase 2 trial – 03/08/2022 at 08:52
(AOF) – Inventiva announced that the FDA has completed the safety assessment of the Investigational New Drug (IND) application. The US health authority has concluded that the proof-of-concept phase 2…
Inventiva announces its participation in several investor conferences in March 2022 – 03/01/2022 at 22:00
Daix (France), Long Island City ( New York, USA) , 1 er March 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of…
Inventiva announces its participation in several investor conferences in March 2022 – 03/01/2022 at 22:00
Daix (France), Long Island City (New York, United States), March 1, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of small molecules…
Inventiva: little reaction
(Boursier.com) — inventive is stable at 11 euros on Tuesday, as the biopharmaceutical company specializing in the clinical development of small molecules taken orally for the treatment of non-alcoholic steatohepatitis…